RNAimmune is a biotechnology startup in the field of messenger RNA (mRNA) technology with more than 20 years’ expertise in handling and optimizing this versatile molecule for medical purposes. The principle of RNAimmune's proprietary technology is the use of mRNA as a data carrier to instruct the human body to produce its own proteins capable of fighting a wide range of diseases. The company applies its technologies for the development of cancer therapies, antibody therapies, the treatment of rare diseases, and prophylactic vaccines.
We develop prophylactic vaccines to help immune systems build responsive mechanisms against serious infectious diseases.
We develop individualized neoantigen based therapeutic vaccines to treat cancer. We also provide early detection and companion diagnosis
We develop mRNA-based therapeutics to treat difficult rare diseases.
RNAimmune’s development pipelines currently focus on mRNA-based vaccines that protect against cancer and respiratory viruses, alongside the development of mRNA cancer immunotherapies.
We’ve developed a synthetic biology based, artificial intelligence aided platform that help us design better mRNAs to invoke the optimal response from our immune system. Current projects that are enabled by our platform include multi-target prophylactic vaccines and cancer vaccines expressing tumor-targeted epitopes.
We have developed several proprietary and novel mRNA delivery methods including lipid nanoparticle (LNP) formulations and Polypeptide Lipid Nanoparticle (PLNP) based carriers. We are able to deliver a wider variety of mRNAs with enhanced intracellular expression and targeted delivery.
We are leveraging advancements in computational protein engineering to optimize vaccines at the protein level for a stronger and more protective immune response.
Our novel self-amplifying mRNAs provide stronger and longer potency for each treatment.
RNAimmune successfully submitted IND application for RSV mRNA vaccine to China Center for Drug Evaluation (CDE) (read more)
RNAimmune licensed out the RV-1770 human RSV Vaccine to Hualan Biological Vaccine Inc. (read more)
FDA Approves RNAimmune’s New mRNA RSV Vaccine for Phase I Trials for Respiratory Disease Prevention (read more)
RNAimmune Receives Investigational New Drug Application Clearance from U.S. FDA for mRNA-Based Respiratory Syncytial Virus Vaccine RV-1770 (read more)
Innoforce’s Partner RNAimmune Granted IND Clearance for RSV mRNA Vaccine from FDA (read more)
Telesis Bio Announces First Commercial Shipment of BioXp® Select DNA Cloning Kit (read more)
Telesis Bio and RNAimmune’s David Brown to Present at SynBioBeta 2023 (read more)
Drug Product Filled with Berkshire Sterile’s Low Loss Fill Process Receives FDA Green Light (read more)
RNAimmune Receives FDA Clearance of Investigational New Drug Application for Phase I Trial of RV-1730 COVID-19 Booster Vaccine (read more)
RNAimmune mRNA Cancer Vaccine Program Accepted for Oral Presentation at the 2023 AACR Annual Meeting (read more)
RNAimmune Secures $27 Million Series A Round of Financing for Development of mRNA Therapeutics and Vaccines (read more)
Sirnaomics’ Spin-Off RNAimmune Secures $10 Million Seed Financing to Advance its mRNA-Based Vaccine and Therapeutic Development (read more)
Codex DNA and RNAimmune Announce Collaboration to Optimize Development of Future mRNA Synthesis and Delivery Kits (read more)
RNAimmune accelerates R&D into mRNA vaccine, drug discovery (read more)
Dr. Shen leads RNAimmune’s strategic vision, and managing relationships investors, partners and regulators. He earned a PhD from Johns Hopkins University School of Medicine and a MD from Shanghai Jiao Tong University School of Medicine. With experience as a surgeon then in drug development at AstraZeneca and Johnson & Johnson, he has led research addressing critical medical needs in infectious disease, oncology, and rare diseases. Dr. Shen’s awards include the Johnson & Johnson Leadership Award in 2018 and the Innovation Award in 2017. His research, published in prestigious journals including Science and Nature, has accumulated over 23,000 citations.
Dr. Long leads international scientific and regulatory operations. He earned a PhD in Genetics from Leeds University, and brings over 30 years of experience in the pharmaceutical industry including key roles at companies including Apptec (now Wuxi Apptec), Genetic Therapy, Sandoz, Novartis, AnGes and Personal Diagnostix. As Vice President of CMC and then Chief Development Officer at Sirnaomics, he played a crucial role in developing STP707, a novel polypeptide nanoparticle drug for solid tumors, now in clinical trials and led GMP process development manufacturing of STP705.
In addition to leading US site operations, Dr. Brown directs Synthetic Biology and CMC department activities. With a PhD from the University of Maryland, his work at the prestigious J. Craig Venter Institute for genomic research included collaborations with GlaxoSmithKline on mRNA vaccine candidates and with Novartis on rapid synthetic generation of influenza vaccines. With publications in leading journals such as Science and Nucleic Acids Research, his expertise encompasses synthetic biology, virology, bioinformatics, assay development, process development and CMC.
A co-founder of RNA-immune, Dr. He leads the R&D team in Guangzhou. Dr. He earned a M.D. Ph.D. from the Guangzhou Institute of Respiratory Disease, specialized in Thoracic Oncology and Respiratory Disease. His ties to the state of Maryland are cemented though a postdoctoral fellowship at the University of Maryland focused on nucleic acid delivery systems and gene therapy. Dr. He has published over 60 articles in leading journals like JCO and Lung Cancer and serves as a reviewer and editor for Frontiers and AME Publication Company. In 2018, he was named the most promising youth oncologist in the “35 under 35” Outstanding Youth Oncologist Talent Competition.
Address
20511 Seneca Meadows Parkway, STE 260
Germantown, MD 20876
Contact
hello@rnaimmune.com
Connect with us on LinkedIn
